Your browser doesn't support javascript.
loading
Preferences for a Clostridioides difficile vaccine among adults in the United States.
Vietri, Jeffrey; Maculaitis, Martine C; Cappelleri, Joseph C; Yu, Holly; Kopenhafer, Lewis; Beusterien, Kathleen.
Afiliação
  • Vietri J; Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Jeffrey.Vietri@pfizer.com.
  • Maculaitis MC; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Martine.Maculaitis@oracle.com.
  • Cappelleri JC; Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Joseph.C.Cappelleri@pfizer.com.
  • Yu H; Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Holly.Yu@pfizer.com.
  • Kopenhafer L; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Lewis.Kopenhafer@oracle.com.
  • Beusterien K; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Kathleen.Beusterien@oracle.com.
Vaccine ; 42(24): 126261, 2024 Oct 24.
Article em En | MEDLINE | ID: mdl-39217776
ABSTRACT

INTRODUCTION:

Clostridioides difficile (C.diff) infection (CDI) causes significant morbidity and mortality among older adults. Vaccines to prevent CDI are in development; however, data on the target population's preferences are needed to inform vaccination recommendations in the United States (US). This study assessed US adults' willingness to receive a C.diff vaccine and examined how vaccine attributes influence their choices.

METHODS:

A cross-sectional online survey with a discrete choice experiment (DCE) was conducted among US adults aged ≥50 years. DCE attributes included effectiveness, duration of protection, reduction in symptom severity, out-of-pocket (OOP) costs, number of doses, and side effects. The DCE included 11 choice tasks, each with two hypothetical vaccine profiles and an opt-out (i.e., no vaccine). Attribute-level preference weights were estimated using hierarchical Bayesian modeling. Attribute relative importance (RI) was compared between select subgroups.

RESULTS:

Of 1216 adults in the analyses, 29.9% reported they knew either 'a little' (20.7%) or 'a lot' (9.2%) about C.diff before the study. A C.diff vaccine was chosen 58.0% of the time (vs. opt-out) across choice tasks. It was estimated that up to 75.0% would choose a vaccine when OOP was $0. Those who were immunocompromised/high-risk for CDI (vs. not) more frequently chose a C.diff vaccine. Decreases in OOP costs (RI = 56.1), improvements in vaccine effectiveness (RI = 17.7), and reduction in symptom severity (RI = 10.3) were most important to vaccine choice. The rank ordering of attributes by importance was consistent across subgroups.

CONCLUSION:

OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copayment may increase uptake. The limited awareness about C.diff among adults presents an opportunity for healthcare providers to educate their patients about CDI prevention.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Bacterianas / Clostridioides difficile / Infecções por Clostridium Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Vaccine Ano de publicação: 2024 Tipo de documento: Article País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Bacterianas / Clostridioides difficile / Infecções por Clostridium Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Vaccine Ano de publicação: 2024 Tipo de documento: Article País de publicação: Holanda